Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBT Margin (2021 - 2025)

Historic EBT Margin for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to 0.29%.

  • Immunocore Holdings' EBT Margin fell 73000.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.41%, marking a year-over-year increase of 107300.0%. This contributed to the annual value of 17.07% for FY2024, which is 73500.0% up from last year.
  • As of Q3 2025, Immunocore Holdings' EBT Margin stood at 0.29%, which was down 73000.0% from 9.9% recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' EBT Margin peaked at 7.59% during Q3 2024, and registered a low of 594.15% during Q4 2021.
  • Its 5-year average for EBT Margin is 110.58%, with a median of 27.0% in 2023.
  • As far as peak fluctuations go, Immunocore Holdings' EBT Margin surged by 5684600bps in 2022, and later plummeted by -108600bps in 2023.
  • Immunocore Holdings' EBT Margin (Quarter) stood at 594.15% in 2021, then surged by 96bps to 25.68% in 2022, then tumbled by -42bps to 36.55% in 2023, then grew by 19bps to 29.53% in 2024, then skyrocketed by 101bps to 0.29% in 2025.
  • Its last three reported values are 0.29% in Q3 2025, 9.9% for Q2 2025, and 6.48% during Q1 2025.